论文部分内容阅读
1984年,东方肿瘤协作组开始对晚期(Ⅲ或Ⅳ期)弥漫混合或弥漫大细胞淋巴瘤患者进行一项随机对照临床试验,以确定这些患者用环磷酰胺、阿霉素、长春新碱和泼尼松(CHOP)的化疗方案治疗的完全缓解率、生存期和毒性与包括博来霉素、阿霉素、环磷酰胺、长春新碱、地塞米松、氨甲喋呤和亚叶酸(m-BACOD)的化疗方案相比的差异。方法从1984年7月到1988年1月,对392例患者进行研究,可评估和适合于分析的325例。患者被随机分配接受 CHOP 或 m-BACOD 治疗并且
In 1984, the Eastern Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large cell lymphoma to determine these patients with cyclophosphamide, doxorubicin, vincristine and The complete remission rate, survival, and toxicity of prednisone (CHOP) chemotherapy regimens included bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and folinic acid (m-BACOD) ) Differences in chemotherapy regimens compared. METHODS: From July 1984 to January 1988, 392 patients were studied and 325 cases that could be evaluated and analyzed. Patients were randomly assigned to CHOP or m-BACOD treatment and